Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins

Conclusion: Our data from a gastric cancer xenograft show the utility of HER2-targeted immuno-PET to inform the tumor response to ADC therapies in combination with modulators of cell-surface target availability. Our studies also demonstrate that statins enhance ADC efficacy in both a cell-line and a patient-derived xenograft model in ways that enable a single-dose administration of the ADC.

Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Brown, E. L., Shmuel, S., Mandleywala, K., Panikar, S. S., Berry, N.-K., Rao, Y., Zidel, A., Lewis, J. S., Pereira, P. M. R. Tags: FEATURED BASIC ARTICLE OF THE MONTH Source Type: research